Atrys Atrys grows by 7.8% and achieves revenues of €115.8 million in the first half of 2025
The company improves its turnover driven by the strong performance of the oncology and diagnostics areas, which recorded increases of 16.9% and 9.8%, respectively
Adjusted EBITDA fell by 13.3% (excluding the extraordinary effects of R&D subsidies, the result shows growth of 3.4%), while gross margin grew by 2.2%
Atrys grows in all its markets, with particular momentum in Spain and Latin America, where Mexico stands out as a driver of expansion
Adjusted EBITDA reached €21.9 million, down 13.3% due to the lower contribution from R&D subsidies compared to 2024. Excluding the effect of grants, adjusted EBITDA grew by 3.4%, reflecting the group's operational strength. Gross margin improved by 2.2% to €73.9 million. Net financial debt remained stable at €163.4 million (+1.3%), with an improvement in financial costs due to the fall in the Euribor.
Meanwhile, adjusted operating cash flow fell by 18.2% compared to the same period last year, to
€15.7 million. This decrease is mainly due to lower grant income and increased CAPEX for
expansion.
The increase in turnover, the improvement in the cost structure, and the absence of extraordinary impairments led the company to record an operating profit of more than €1 million in the first half of the year, compared to a loss of €5.2 million in the same period in 2024. Atrys also reduced its consolidated loss by 43.3%, reflecting a solid financial performance.
Marian Isach, Atrys, CEO chief executive officer, has pointed out that: "The results for the first half of the year reaffirm the strength of our main business areas, while confirming the great potential for expansion in all our markets, with particular dynamism in Latin America. Our commitment is to continue driving the growth of our core business with a firm commitment to innovation, bringing the most advanced and precise therapies to patients. He added: "These advances are supported by strategic milestones such as the opening of the Institute of Advanced Oncology in Madrid, the expansion of medical oncology in Mexico, and the promotion of telemedicine and genetics in Spain, Portugal, and Latin America". Growth drivers: medical oncology, advanced radiotherapy, and geneticsDuring the first six months of the year, Atrys strengthened its leadership in its strategic areas. In Spain, the Oncology division grew by 21% thanks to new commercial agreements and increased activity, while in Mexico, where the company already operates three medical oncology centers, it achieved a 36% increase, while preparing two new openings in the region in the second half of 2025.
In radiotherapy, and true to its innovative DNA, the company inaugurated the IOA Madrid in June, equipped with the first Varian Edge accelerator in Spain, which introduces innovations such as adaptive radiotherapy and free-breathing radiosurgery, improving efficacy and the patient experience. In diagnostics, revenues increased to €35.1 million, driven by telemedicine (+6.2%) and strong growth in genetics and pathology (+22.6%). In addition, nuclear medicine increased its sales by 5.7% and obtained authorization to expand its teragnosis service, an innovative personalized therapy that combines diagnosis and treatment in the same molecular target, reducing side effects and increasing precision. Sustained growth and diversified geographic profile
In the first half of 2025, Atrys consolidated the growth of its core business in all its markets, with notable progress in Spain (+8%, €86.5 million) and Latin America (+8%, €21.4 million). Within the region, Mexico stood out with strong performance (+36%), becoming the company's second most important market in just three years, alongside growth in Colombia (+12.5%), Chile (+1.6%) and the expansion of medical oncology in Brazil. In Portugal, revenues increased by 7.3% (€7.9 million) and the country remains focused on efficiencies and strategic agreements.
Focus on organic growth and value creationAfter completing the integration of acquisitions, 2025 marks a turning point for Atrys, which is reviewing its portfolio to prioritize businesses with greater international projection and cash generation capacity. "Our goal is clear: to grow where we are leaders, with differential innovation and a capital structure that maximizes returns for shareholders," says Marian Isach.
Today, Monday, September 22, at 10:00 a.m., Atrys will hold a webcast to present its results for the first half of 2025. Register via this link: https://streamstudio.world-television.com/1445-2730-41931/es
About Atrys GroupAtrys is a global healthtech company that provides medical services that maximize efficiency in prevention, diagnosis, and precision medicine through innovative technologies. It is a leader in telemedicine, cancer treatment, and occupational risk prevention. It has a team of more than 2,000 professionals, is present in seven countries in Europe and Latin America, and is the only publicly traded company in the healthcare technology sector in Spain. The company structures its activity around two main business areas: precision medicine and preventive medicine. The precision medicine area comprises diagnostic activities-telemedicine, nuclear medicine, pathological and molecular anatomy-and cancer treatment-medical oncology and advanced radiotherapy-while the preventive medicine area focuses on prevention and health promotion, serving more than one million people through ASPY's network of more than 200 branches throughout Spain.
Media contactsDiana Barriga
Atrys dbarriga@atryshealth.com
+34 649 042 525
Almudena Guerra
Roman a.guerra@romanrm.com
+34 659 215 222